Clinical Trial: Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY(R) (US-Sourced YERVOY(R)) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07176650) titled 'Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY(R) (US-Sourced YERVOY(R)) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma' on Sept. 01.

Brief Summary: This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY(R) in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Cond...